Ixekizumab, bimekizumab, and secukinumab ranked highest for achieving therapeutic benchmarks among 21 comparators for scalp psoriasis.
A network meta-analysis of randomized trials in scalp psoriasis, published in the Journal of Cosmetic Dermatology, was conducted by a multinational team. First author, Aditya Gupta, MD, PhD, MBA, is professor of dermatology with Temerty Faculty of Medicine at the University of Toronto. The following paper excerpts were edited for length and clarity.
What prompted this review?
Gupta and colleagues: Various therapeutic agents have been used to treat scalp psoriasis; among the most recent ones are the immunomodulatory agents such as monoclonal antibodies, interleukin-17A antagonists, phosphodiesterase 4 inhibitors, and tyrosine kinase 2 inhibitors. To our knowledge, the first network meta-analysis that evaluated the management of scalp psoriasis using biologics compared the relative efficacy of immunomodulatory agents. However, the efficacy of several other immunomodulatory monotherapies has been reported since.
The current study investigated the comparative effectiveness of immunomodulatory treatments using data from the updated evidence base.
